Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma.

导出 OA

翻译打印收藏纠错

作者： Tomi,Jun ^[1] ; Noah M,Hahn ^[2] ; Guru,Sonpavde ^[3] ; Constantine,Albany ^[4] ; Gary R,MacVicar ^[5] ; Ralph,Hauke ^[6] ; Mark,Fleming ^[7] ; Theodore,Gourdin ^[8] ; Bagi,Jana ^[9] ; William K,Oh ^[10] ; Patricia,Taik ^[1] ; Huan,Wang ^[2] ; Ajay Ramakrishnan,Varadarajan ^[1] ; Andrew,Uzilov ^[1] ; Matthew D,Galsky ^[1]

作者单位： Sema4, Stamford, CT, USA. ^[1] The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ^[2] Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA. ^[3] University of Alambama at Birmingham, Birmingham, AL Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. ^[4] Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA. ^[5] Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL Illinois CancerCare, Peoria, IL, USA. ^[6] Nebraska Cancer Specialists/ Nebraska Methodist Hospital, Omaha, NE, USA. ^[7] Virginia Oncology Associates, Norfolk, VA, USA. ^[8] Medical University of South Carolina Hollings Cancer Center, Charleston, SC, USA. ^[9] University of Texas Medical Branch at Galveston, Galveston, TX, USA. ^[10]

关键词 cisplatin-ineligible everolimus genomic paclitaxel urothelial cancer